Live Breaking News & Updates on Telix Chief Medical Officer

Stay updated with breaking news from Telix chief medical officer. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

ProstACT SELECT Study of TLX591 Interim Readout: Positive Results Confirm Safety and Tolerability

The study has achieved its primary objectives, confirming the safety and tolerability profile of TLX591 administered in two doses, two weeks apart in combination with standard of care (SoC) Preliminary activity demonstrates meaningfulPSA[1] reduction; monitoring of patients is ongoing, including for rPFS[2] Findings reinforce the potential advantages of this first-in-class radio-antibody drug conjugate (rADC) investigational therapy, consistent with previous clinical studies of TLX591[3] MELBOURNE, Australia, Oct. 19, 2023 /PRNewswire/ Telix Pharmaceuticals Limited (ASX: TLX, Telix, the Company)today announces positive preliminary results from the Phase I ProstACT SELECT study of its rADC therapy candidate TLX591 (Lutetium (177Lu) rosopatamab tetraxetan) for prostate-specific membrane antigen (PSMA) positive metastatic castration-resistant prostate cancer (mCRPC). The purpose of the SELECT study (ClinicalTrials.gov ID: NCT04786847)was to evaluate the utility of PSMA imaging to select ....

New York , United States , United Kingdom , Scottt Tagawa , Nat Lenzo , Colin Hayward , Kyahn Williamson , Corporate Communications , Telix Pharmaceuticals Limited Disclosure Committee , Drug Administration , Prnewswire Telix Pharmaceuticals Limited , European Union , Telix Pharmaceuticals , Australian Therapeutic Goods Administration , Genesiscare Group Clinical , Australian Securities Exchange , Health Canada , Pharmaceuticals Limited , Genesiscare Group Clinical Director Theranostics , Telix Chief Medical Officer , Marketing Authorisation Applications , Telix Pharmaceuticals Limited , The Study Has Achieved Its Primary Objectives , Onfirming The Safety And Tolerability Profile Of Tlx591 Administered In Two Doses , Wo Weeks Apart In Combination With Standard Of Care Soc Preliminary Activity Demonstrates Meaningfulpsa 1 Reduction Monitoring Patients Is Ongoing , Ncluding For Rpfs 2 Findings Reinforce The Potential Advantages Of This First In Class Radio Antibody Drug Conjugate Radc Investigational Therapy ,

ProstACT SELECT Study of TLX591 Interim Readout: Positive Results Confirm Safety and Tolerability

ProstACT SELECT Study of TLX591 Interim Readout: Positive Results Confirm Safety and Tolerability
streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.

New York , United States , United Kingdom , Colin Hayward , Scottt Tagawa , Nat Lenzo , Kyahn Williamson , Prnewswire Telix Pharmaceuticals Limited , Australian Therapeutic Goods Administration , Telix Pharmaceuticals , Drug Administration , Corporate Communications , Australian Securities Exchange , European Union , Telix Pharmaceuticals Limited Disclosure Committee , Genesiscare Group Clinical , Health Canada , Pharmaceuticals Limited , Genesiscare Group Clinical Director Theranostics , Telix Chief Medical Officer , Marketing Authorisation Applications , Telix Pharmaceuticals Limited ,

Telix Pharmaceuticals Limited: ProstACT SELECT Study of TLX591 Interim Readout: Positive Results Confirm Safety and Tolerability

Telix Pharmaceuticals Limited: ProstACT SELECT Study of TLX591 Interim Readout: Positive Results Confirm Safety and Tolerability
finanznachrichten.de - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from finanznachrichten.de Daily Mail and Mail on Sunday newspapers.

New York , United States , United Kingdom , Colin Hayward , Ihre Chancen , Kyahn Williamson , Scottt Tagawa , Nat Lenzo , Indiens Wirtschaft , Telix Pharmaceuticals , Genesiscare Group Clinical , Australian Securities Exchange , Drug Administration , Australian Therapeutic Goods Administration , Health Canada , Prnewswire Telix Pharmaceuticals Limited , Corporate Communications , Telix Pharmaceuticals Limited Disclosure Committee , European Union , Pharmaceuticals Limited , Genesiscare Group Clinical Director Theranostics , Telix Chief Medical Officer , Marketing Authorisation Applications , Telix Pharmaceuticals Limited , Der Indien , Die Highlights ,

ProstACT SELECT Study of TLX591 Interim Readout: Positive Results Confirm Safety and Tolerability

/PRNewswire/ Telix Pharmaceuticals Limited (ASX: TLX, Telix, the Company) today announces positive preliminary results from the Phase I ProstACT SELECT. ....

New York , United States , United Kingdom , Colin Hayward , Kyahn Williamson , Nat Lenzo , Scottt Tagawa , Health Canada , Australian Securities Exchange , Australian Therapeutic Goods Administration , Prnewswire Telix Pharmaceuticals Limited , Drug Administration , Telix Pharmaceuticals , Telix Pharmaceuticals Limited Disclosure Committee , European Union , Genesiscare Group Clinical , Corporate Communications , Pharmaceuticals Limited , Genesiscare Group Clinical Director Theranostics , Telix Chief Medical Officer , Marketing Authorisation Applications , Telix Pharmaceuticals Limited ,

ProstACT SELECT Study of TLX591 Interim Readout: Positive Results Confirm Safety and Tolerability

/PRNewswire/ Telix Pharmaceuticals Limited (ASX: TLX, Telix, the Company) today announces positive preliminary results from the Phase I ProstACT SELECT. ....

New York , United States , United Kingdom , Kyahn Williamson , Nat Lenzo , Colin Hayward , Scottt Tagawa , Corporate Communications , Drug Administration , Telix Pharmaceuticals , Australian Therapeutic Goods Administration , Prnewswire Telix Pharmaceuticals Limited , Health Canada , Genesiscare Group Clinical , Telix Pharmaceuticals Limited Disclosure Committee , Australian Securities Exchange , European Union , Pharmaceuticals Limited , Genesiscare Group Clinical Director Theranostics , Telix Chief Medical Officer , Marketing Authorisation Applications , Telix Pharmaceuticals Limited ,